High sensitive metody stanovení srdečních troponinů v současné klinické praxi

Miroslav Engliš, Radek Pudil

Interv Akut Kardiol. 2011;10(3):96-98  

Outpatient catheterization in the Czech Republic

David Horák, Ivo Bernat

Interv Akut Kardiol. 2011;10(3):99-101  

Heart catheterizations has been recognized for several decades as indispensible method for evaluation of broad spectrum of heart disease and particularly in patients with coronary heart disease. Diagnostic and interventional procedures are performed in huge number of patients worldwide and require significant personal and financial resources. In order to cut the costs there has been in early ninetieth introduced outpatient catheterizations. With new, more advanced devices and particularly with introducing radial approach as routine arterial entry site, there is increasing number of outpatient procedures.

Biomarkers in acute pulmonary embolism

Jiří Widimský

Interv Akut Kardiol. 2011;10(3):102-108  

Biomarkers may significantly improve the quantification of risk in normotensive patients with acute pulmonary embolism. Biomarkers are divided into 1) troponins, 2) natriuretic peptides, and 3) new biomarkers. A meta-analysis including 20 studies published since 1998 and comprising 1,985 patients with acute pulmonary embolism showed that elevated troponins are linked with an increased risk of death and an increased risk of major complications. Another meta-analysis including 1,366 only normotensive patients with acute pulmonary embolism from 9 studies, however, showed that increased troponins in normotensive patients fail to identify patients...

Drug-coated balloon

Ivo Varvařovský

Interv Akut Kardiol. 2011;10(3):109-112  

Drug-coated balloon (drug-eluting balloon, DEB) emerged as effective treatment of in-stent restenosis with great potential for the extension of treatment indications for other areas of coronary interventions. Drug-eluting balloon may become a good alternative for drug-eluting stents with comparable effectiveness and better safety profile. However, great expectations are attenuated with the first results of the clinical trial PEPCAD III.

Imaging techniques and image integration during radiofrequency catheter

Alan Bulava

Interv Akut Kardiol. 2011;10(3):114-120  

ablation for atrial fibrillation – survey of literature and our own experience Radiofrequency catheter ablations (RFCA) for atrial fibrillation (AF) belong to the established non-pharmacological therapy of this arrhythmia. The goal of the therapy is to create series of circumferential and linear lesions in either left atrium or both atria to eliminate triggers and perpetuators of AF. We have witnessed an enormous technical and methodological development in this area recently with the aim to increase efficacy and safety of RFCA for AF. One of such modality is different imaging techniques, which allow for a more precise definition of...

The use of Impella 2.5 in high-risk percutaneous coronary intervention

Jan Pešek, Ivo Bernat, Jiří Koza, Michal Šmíd, Jakub Čech, Vratislav Pechman, Milan Hromádka, Jiří Široký, Vladimír Mikulenka, Viktor Zlocha, Tomáš Hájek, Richard Rokyta

Interv Akut Kardiol. 2011;10(3):122-126  

The Impella 2.5 is the left ventricle assist device dedicated for short-term circulatory support up to five days. This device is introduced transfemorally, across the aortic valve, used for expelling of blood from the left ventricle to ascending aorta up to 2,5 l/min. The authors describe five case reports about the use of this circulatory support in one year periode (October 2009 to September 2010), in cases of percutaneous coronary intervention with expected high-risk of periprocedural cardiac arrest. The patients were 4 men and 1 woman, age 58–73 years, with severe systolic left ventricular dysfunction, in which cardiac surgery was...

Abstrakta z XXI. workshopu intervenční kardiologie 7.- 8. 4. 2011, Výukové centrum LF UK, areál FN Hradec Králové

Interv Akut Kardiol. 2011;10(3):141-142  

Ticagrelor - first reversible inhibitor of ADP receptor P2Y12

Jan Bultas

Interv Akut Kardiol. 2011;10(3):128-136  

Antiplatelet therapy based on the inhibition of the platelet P2Y12 receptor for adenosine diphosphate (ADP) along with the inhibition of thromboxane A2 production by acetylsalicylic acid is among the well-established therapeutic approaches for reducing thrombotic complications in patients at a high risk. The use of the gold standard – clopidogrel – is associated with an approximately 30 % rate of resistance to treatment when there is polymorphism in the bioactivating enzymes. This fact has resulted in the introduction of new and more reliable inhibitors of ADP receptors. Ticagrelor is the first of a new generation of non-thienopyridine...

Vzpomínka na doc. MUDr. Stanislava Janouška, CSc.

prof. MUDr. Jindřich Špinar, CSc.

Interv Akut Kardiol. 2011;10(3):139  

Rokitanského den v Hradci Králové

Radek Pudil

Interv Akut Kardiol. 2011;10(3):140